Stocks · News reference
Adagene Inc. has finished enrolling patients for its Phase 2 dose-optimization trial of muzastotug in combination with Merck's anti-PD-1 therapy, KEYTRUDA, for late-line colorectal cancer.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Merck and Eisai have received a Complete Response Letter (CRL) from regulatory authorities regarding their application for the LENVIMA and KEYTRUDA combination as a first-line treatment for unresectable hepatocellular carcinoma.
BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.
Halozyme Therapeutics raised its 2026 revenue guidance to $1.86-$1.925B driven by 44% growth in third-quarter royalties to $341M from established therapies and newer subcutaneous launches. The company is expanding its ENHANZE pipeline with new partner collaborations and preparing Hypercon for clinical testing, while facing a European patent dispute with Merck over KEYTRUDA Qlex.
Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
Merck Healthcare and JD Health have entered into a strategic partnership to prioritize the online launch of new drugs on the JD Health platform over the next three years.